FDA Approves Tirzepatide (Mounjaro) for Type 2 Diabetes

May 13, 2022 08:29pm

Announced on May 13, the approval indicates Eli Lilly and Company's novel dual GLP-1/GIP agonist, tirzepatide (Mounjaro), for use as an adjunct to diet and exercise to improve blood sugar in adult patients with type 2 diabetes.

Prescription Drug Insurance Out of Reach for Many Older Adults
At-Home Outcomes Following Inpatient Rehabilitation for COPD Improved by Rehabilitation App
News Roundup: May 9 to May 13
Many Biologics for Severe Asthma Can Be Self-Administered at Home — Patients Prefer It